Company news
Faron Pharmaceuticals Oy news in 2018
Faron Pharmaceuticals Oy's news releases, calls and decks from 2018, newest first.
Traumakine update - YODA results
December 19, 2018
First patient dosed in phase I/II MATINS study
December 14, 2018
Patient subgroup identified from INTEREST trial
December 5, 2018
Faron receives CTA approval for Clevegen
December 3, 2018
PDMR Dealings
November 6, 2018
INTEREST trial update presented at ESICM
October 22, 2018
Director/PDMR Shareholding
September 18, 2018
Faron announces CTA filing for Clevegen
September 17, 2018
Interim Results
September 13, 2018
New data published on Clever-1 function
September 12, 2018
Clevegen successful toxicity studies
June 28, 2018
Biomarker analysis of Phase III INTEREST trial
June 14, 2018
AGM Statement
May 31, 2018
PDMR Shareholding
May 16, 2018
Update on the Phase III INTEREST trial
May 11, 2018
Top line data from the Phase III INTEREST trial
May 8, 2018
Notice of Full Year Results
March 21, 2018
Results of Placing & Issue of Equity
February 21, 2018
Proposed Placing to raise up to £15m
February 16, 2018
Second Traumakine manufacturing site established
February 5, 2018
Faron Announces Clevegen Grant of European Patent
February 1, 2018
FDA grants Fast Track Designation for Traumakine®
January 29, 2018
FDA approval of Faron's Traumakine® IND
January 24, 2018
Decks in 2018
- Shareholder Meeting (May 2018)
Shareholder meeting · 24 slides · May 31, 2018